Literature DB >> 8287224

Accumulation of p53 protein as an indicator for p53 gene mutation in breast cancer. Occurrence of false-positives and false-negatives.

D Lohmann1, C Ruhri, M Schmitt, H Graeff, H Höfler.   

Abstract

Accumulation of p53 protein resulting in levels detectable by immunohistochemistry (IHC) has been proposed as an indicator of mutation of the p53 gene. We have investigated a panel of 23 fresh-frozen breast cancers by IHC (PAb 1801), Southern and Northern blot analysis, and direct sequencing of the mutation hot spot regions (exons 5-8) of the p53 gene. Three tumors (13%) showed an intense nuclear staining in the majority of malignant cells, but only one of these showed a mutation of the p53 gene (codon 237, Arg to His). Furthermore, a mutation (5-bp deletion) was identified in a tumor that showed no p53 immunoreactivity. Our results indicate that accumulation of p53 protein, as detectable by IHC, is not a reliable indicator for p53 gene mutation in human breast cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8287224

Source DB:  PubMed          Journal:  Diagn Mol Pathol        ISSN: 1052-9551


  9 in total

1.  Tumor specific activation of the VEGF/KDR angiogenic pathway in a subset of locally advanced squamous cell head and neck carcinomas.

Authors:  A Giatromanolaki; M I Koukourakis; E Sivridis; P E Thorpe; R A Brekken; S Konstantinos; G Fountzilas; K C Gatter; A L Harris
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  Germ cell tumors of the testis overexpress wild-type p53.

Authors:  L Guillou; A Estreicher; P Chaubert; J Hurlimann; A M Kurt; G Metthez; R Iggo; A C Gray; P Jichlinski; H J Leisinger; J Benhattar
Journal:  Am J Pathol       Date:  1996-10       Impact factor: 4.307

3.  p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors.

Authors:  T Günther; R Schneider-Stock; J Rys; A Niezabitowski; A Roessner
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

4.  Rational Manual and Automated Scoring Thresholds for the Immunohistochemical Detection of TP53 Missense Mutations in Human Breast Carcinomas.

Authors:  Nicholas J Taylor; Nana Nikolaishvili-Feinberg; Bentley R Midkiff; Kathleen Conway; Robert C Millikan; Joseph Geradts
Journal:  Appl Immunohistochem Mol Morphol       Date:  2016-07

5.  p53 mutations in classic and pleomorphic invasive lobular carcinoma of the breast.

Authors:  Cigdem Ercan; Paul J van Diest; Bram van der Ende; John Hinrichs; Peter Bult; Horst Buerger; Elsken van der Wall; Patrick W B Derksen
Journal:  Cell Oncol (Dordr)       Date:  2012-02-22       Impact factor: 6.730

6.  Frequent p53 mutation in brain (fetal)-type glycogen phosphorylase positive foci adjacent to human 'de novo' colorectal carcinomas.

Authors:  S Shimada; K Shiomori; S Tashima; J Tsuruta; M Ogawa
Journal:  Br J Cancer       Date:  2001-06-01       Impact factor: 7.640

7.  TP53 mutation is associated with a poor clinical outcome for non-small cell lung cancer: Evidence from a meta-analysis.

Authors:  Jincui Gu; Yanbin Zhou; Lixia Huang; Weijun Ou; Jian Wu; Shaoli Li; Junwen Xu; Jinlun Feng; Baomo Liu
Journal:  Mol Clin Oncol       Date:  2016-10-21

8.  Utility of a dual immunostain cocktail comprising of p53 and CK20 to aid in the diagnosis of non-neoplastic and neoplastic bladder biopsies.

Authors:  Isil Z Yildiz; Rosemary Recavarren; Henry B Armah; Sheldon Bastacky; Rajiv Dhir; Anil V Parwani
Journal:  Diagn Pathol       Date:  2009-10-14       Impact factor: 2.644

9.  Mutations in p53, p53 protein overexpression and breast cancer survival.

Authors:  Pavel Rossner; Marilie D Gammon; Yu-Jing Zhang; Mary Beth Terry; Hanina Hibshoosh; Lorenzo Memeo; Mahesh Mansukhani; Chang-Min Long; Gail Garbowski; Meenakshi Agrawal; Tara S Kalra; Mia M Gaudet; Susan L Teitelbaum; Alfred I Neugut; Regina M Santella
Journal:  J Cell Mol Med       Date:  2008-10-16       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.